06:47:32 Europe / Stockholm
Svenska | English

Pharma Equity Group

Attachments

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2024-11-15 Quarterly Report 2024-Q3
2024-08-16 Quarterly Report 2024-Q2
2024-06-03 Extra General Meeting 2024
2024-05-16 Quarterly Report 2024-Q1
2024-04-17 Ex-date Ordinary Dividend PEG 0.00 DKK
2024-04-16 Annual General meeting
2024-03-20 Year-end Report 2023
2023-11-02 Extra General Meeting 2023
2023-08-16 Quarterly Report 2023-Q2
2023-04-26 Ex-date Ordinary Dividend PEG 0.00 DKK
2023-04-25 Annual General meeting
2023-03-31 Year-end Report 2022
2022-10-27 Extra General Meeting 2022
2022-08-31 Quarterly Report 2022-Q2
2022-04-26 Ex-date Ordinary Dividend PEG 0.00 DKK
2022-04-25 Annual General meeting
2022-03-31 Year-end Report 2021
2022-01-21 Year-end Report 2021
2021-11-10 Extra General Meeting 2021
2021-08-30 Quarterly Report 2021-Q2
2021-05-03 Ex-date Ordinary Dividend PEG 0.00 DKK
2021-04-29 Annual General meeting
2020-08-24 Quarterly Report 2020-Q2
2020-04-28 Ex-date Ordinary Dividend PEG 0.00 DKK
2020-04-27 Annual General meeting
2020-03-30 Year-end Report 2019
2019-11-01 Split PEG 10:1
2019-08-23 Quarterly Report 2019-Q2
2019-04-29 Ex-date Ordinary Dividend PEG 0.00 DKK
2019-04-26 Annual General meeting
2019-03-29 Year-end Report 2018
2019-02-26 Extra General Meeting 2019
2018-08-24 Quarterly Report 2018-Q2
2018-05-01 Ex-date Ordinary Dividend PEG 0.00 DKK
2018-04-30 Annual General meeting
2018-04-06 Year-end Report 2017
2017-08-25 Quarterly Report 2017-Q2
2017-05-01 Ex-date Ordinary Dividend PEG 0.00 DKK
2017-04-28 Annual General meeting
2016-08-25 Quarterly Report 2016-Q2
2016-05-12 Quarterly Report 2016-Q1
2016-05-02 Ex-date Ordinary Dividend PEG 0.00 DKK
2016-04-29 Annual General meeting
2016-03-31 Year-end Report 2015
2016-02-24 Split PEG 1:10
2016-02-18 Extra General Meeting 2016
2015-10-21 Quarterly Report 2015-Q3
2015-07-15 Quarterly Report 2015-Q2
2015-05-01 Ex-date Ordinary Dividend PEG 0.00 DKK
2015-04-30 Annual General meeting
2015-04-14 Quarterly Report 2015-Q1
2015-03-31 Year-end Report 2014
2015-02-02 Extra General Meeting 2015
2014-12-22 Extra General Meeting 2014
2014-11-07 Quarterly Report 2014-Q3
2014-08-15 Quarterly Report 2014-Q2
2014-05-09 Quarterly Report 2014-Q1
2014-04-30 Annual General meeting
2014-04-01 Ex-date Ordinary Dividend PEG 0.00 DKK
2014-03-31 Year-end Report 2013
2013-11-06 Quarterly Report 2013-Q3
2013-08-16 Quarterly Report 2013-Q2
2013-05-07 Quarterly Report 2013-Q1
2013-04-30 Annual General meeting
2013-04-01 Ex-date Ordinary Dividend PEG 0.00 DKK
2013-03-29 Year-end Report 2012
2012-11-06 Quarterly Report 2012-Q3
2012-08-17 Quarterly Report 2012-Q2
2012-05-07 Quarterly Report 2012-Q1
2012-05-01 Ex-date Ordinary Dividend PEG 0.00 DKK
2012-04-30 Annual General meeting
2012-03-30 Year-end Report 2011
2011-11-04 Extra General Meeting 2011
2011-05-02 Ex-date Ordinary Dividend PEG 0.00 DKK
2011-04-29 Annual General meeting
2010-05-03 Ex-date Ordinary Dividend PEG 0.00 DKK

Description

CountryDenmark
ListSmall Cap Copenhagen
SectorHealth care
IndustryMedical technology
Pharma Equity Group utvecklar nya läkemedel för lokal behandling av allvarliga och livshotande inflammatoriska sjukdomar för vilka det för närvarande inte finns någon adekvat behandling. Bolaget använder ompositionering av befintliga läkemedel och tar läkemedelskandidater till ett kliniskt fas III-stadium, varefter de överlämnas till en strategisk partner som kommer att slutföra utvecklingen av produkterna och föra ut dem på marknaden, antingen självständigt eller i samarbete med bolaget.
Results of extraordinary general meeting in Pharma Equity Group A/S
2024-06-03 16:17:47
  
  
 Results of extraordinary general meeting in Pharma Equity Group A/S
  

3 June 2024
Company announcement no. 19

 

Pharma Equity Group A/S today held an extraordinary general meeting with the following results:

 

  1. The company's share capital will be reduced by a nominal value of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00 to a nominal value of DKK 102,296,388.30 by allocation to a specific reserve pursuant to section 188(1)(3) of the Danish Companies Act. The capital reduction will be made by a proportional reduction of the denomination of all the company's shares, meaning that the denomination of the shares will be reduced from DKK 1.00 to DKK 0.1.
 

Prior to the completion of the capital reduction, the company's creditors will be encouraged to give notice on any claims against the company for a period of four weeks. The request will be published in the Danish Business Authority's IT-system.

 

  1. The chair of the general meeting was, with a right of substitution, authorised to file the resolution adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require to register or approve the resolution adopted.
 

 

For further information, please contact:

 
 Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
  

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

 

 

Attachments

Announcement no. 19 UK

Source GlobeNewswire Nordic
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

An email has been sent to the given address. To login please click "Login" in that email to verify your account

Companies

Press releases